Understanding Borderline Personality Disorder (BPD)

Borderline Personality Disorder (BPD) is a complex and often contentious diagnosis in mental health. Despite increasing awareness in the age of “it’s okay to not be okay,” stigma around BPD remains high.

BPD is characterized by:

• Emotion dysregulation

• Impulsivity

• Extreme rejection sensitivity

• Unstable self-concept

• Volatile behaviour
  (Gunderson et al., 2018)

It is often considered a “female disorder,” with women diagnosed up to 75% more often than men. Whether this difference reflects sampling bias, diagnostic bias, biological differences, or sociocultural factors is still debated (Skodol & Bender, 2003).

Causes and Contributing Factors

Like many mental health disorders, childhood trauma is strongly linked to BPD. This is especially clear when viewed in a multifactorial etiological model (Ball & Links, 2009).

A well-established link exists between childhood sexual abuse and BPD in women (Temes et al., 2020). Early trauma’s role in BPD development is now a critical focus in research (Yuan et al., 2023).

Current Treatment Options and Their Limitations

Evidence-based therapies for BPD include:

• Dialectical Behavioural Therapy (DBT)

• Mentalisation-Based Therapy (MBT)

• Transference-Focused Psychotherapy (TFP)

While these approaches are more effective than treatment as usual, their impact is only small to moderate (Stoffers et al., 2012; Cristea et al., 2017).

Currently:

• No pharmacological treatments are proven effective for BPD (Zeifman & Wagner, 2020).

• Many patients still experience significant life disruption despite therapy.

This treatment gap creates an urgent need for novel interventions.

Psychedelic Therapy: A New Frontier for BPD Treatment

A growing body of research on psychedelic-assisted therapy (PAT) shows promising results for conditions such as:

• Major Depressive Disorder

• PTSD

• Substance Use Disorders

• OCD
  (Sessa et al., 2019)

Because these conditions often co-occur with BPD and share overlapping symptoms, psychedelics may also benefit BPD.

Key hypothesis: Psychedelics help by catalyzing trauma processing, reducing the emotional triggers that maintain mental illness (Inserra et al., 2018).

Evidence Linking Psychedelics to BPD Symptom Improvement

Although no direct studies have examined psychedelics for BPD as a primary diagnosis, several have included participants with BPD traits. Results indicate similar positive outcomes in these individuals compared to others (Zeifman & Wagner, 2020).

Psychedelics may improve core BPD-related symptoms:

1. Emotional Dysregulation

2. Behavioural Dysregulation

3. Self-Identity Disturbances

4. Social Functioning Issues

1. Emotional Dysregulation and Psychedelics

Emotional dysregulation—a mix of emotional sensitivity, negative affect, and poor emotion regulation strategies—is considered central to BPD (Zeifman & Wagner, 2020).

It is linked to:

• Overactive limbic system (emotion generation)

• Reduced prefrontal activity (top-down control)
  (Schulze et al., 2016)

Key findings:

• Ayahuasca lowered emotional dysregulation within 24 hours in a community sample, including participants with BPD traits (Domínguez-Clavé et al., 2019).

• Lifetime psychedelic use is linked to lower emotion dysregulation in general populations (Thiessen et al., 2018).

2. Behavioural Dysregulation and Psychedelics

BPD often involves behaviours such as:

• Aggression

• Substance abuse

• Suicidality

• Impulsivity
  (APA, 2013)

Research highlights:

• Psilocybin-assisted psychotherapy increased behavioural control (Bogenschutz et al., 2018).

• Ritual ayahuasca use reduced impulsivity (Fernández et al., 2014).

• Psychedelics are linked to decreased aggression (Zeifman & Wagner, 2020).

• LSD and other psychedelics have shown reductions in substance abuse (Krebs & Johansen, 2012).

• Psychedelics may reduce suicidal behaviours, even in BPD-inclusive samples (Grunebaum et al., 2017; Murrough et al., 2015).

3. Mindfulness and Psychedelic Therapy

Mindfulness, mentalization, acceptance, and decentring (observing thoughts and emotions) are vital for emotional stability.

People with BPD often score lower in these skills (Zeifman & Wagner, 2020).

PAT outcomes:

• Ayahuasca ceremonies increase acceptance and decentring (Domíngues-Clavé et al., 2019; Soler et al., 2018).

4. Self-Identity and Psychedelics

An unstable self-identity is another BPD hallmark (APA, 2013).

While no study directly examines PAT’s effect on self-concept stability, evidence suggests psychedelics promote:

• Self-compassion

• Self-acceptance
  (Zeifman & Wagner, 2020)

5. Social Functioning and Psychedelics

BPD can be isolating, with strained relationships due to emotional and behavioural instability.

Studies show:

• Ketamine-assisted therapy improved interpersonal sensitivity and social functioning (Krupitsky & Grinenko, 1996).

• Psilocybin and MDMA-assisted therapy improved relationship quality (Zeifman & Wagner, 2020).

Safety Concerns with Psychedelic Therapy in BPD

Despite promising evidence, many retreat and clinical PAT programs exclude participants with BPD due to safety concerns:

• Potential for suicidality risk

• Possible distress from “bad trips”

• Emotional instability during psychedelic experiences

However:

• Across ~10 PAT studies including BPD participants, no serious adverse effects were reported (Zeifman & Wagner, 2020).

• Serotonergic psychedelics (e.g., LSD, ayahuasca) have low dependence potential (Hamill et al., 2019).

Recommendations for Future Research and Practice

• Initial trials should exclude participants with recent severe self-harm or suicidal behaviours.

• Follow established PAT guidelines (Johnson et al., 2008):

  • Controlled clinical setting

  • Therapist support and sedatives if needed

  • Preparation and integration sessions

Combining PAT with existing therapies like DBT could enhance outcomes. For example, MDMA-assisted psychotherapy with adapted DBT showed promise for autistic adults with social anxiety (Danforth et al., 2018).

Conclusion

While there is no direct research on psychedelic-assisted therapy for BPD, existing studies suggest potential benefits for key symptoms: emotional dysregulation, behavioural instability, poor self-identity, and impaired social functioning.

If applied with proper safety measures, PAT could be a valuable addition to the limited treatment options for BPD—offering hope to an underserved patient population.